\n<\/p>\n
HONG KONG SAR –\u00a0EQS Newswire\u00a0– 10 March 2021 – A
According to Frost & Sullivan, the patient populations of
“We are excited to collaborate with Uni-Bio to explore the
“Being competitive in the biotechnology industry requires
HONG KONG SAR –\u00a0EQS Newswire\u00a0– 10 March 2021 – A
fully integrated biopharmaceutical company — Uni-Bio Science Group Limited (the
“Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK)
is pleased to announce that the company and DotBio Pte. Ltd. (“DotBio”) formed
a partnership to co-develop next generation, best-in-class therapeutics for patients
with retinal …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/13088"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=13088"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/13088\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=13088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=13088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=13088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nfully integrated biopharmaceutical company — Uni-Bio Science Group Limited<\/a> (the
\n“Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK)
\nis pleased to announce that the company and DotBio Pte. Ltd. (“DotBio”) formed
\na partnership to co-develop next generation, best-in-class therapeutics for patients
\nwith retinal diseases, such as age-related macular degeneration (AMD), diabetic
\nmacular edema (DME), retinal vein occlusion (RVO), and myopic choroidal
\nneovascularization (mCNV). These diseases are major causes of visual impairment
\nand blindness worldwide. The partnership will involve a close collaboration
\nbetween the two companies. Under the agreement, DotBio’s Hong Kong subsidiary, DotBioHK,
\nis responsible for generating multiple
\nmulti-valent and\/or bi-specific stabilized and humanized single-domain antibody
\ncandidates for various targets using DotBio’s proprietary DotBody technology. Uni-Bio
\nis responsible for Chemical Manufacturing Control (CMC), Investigation New Drug
\n(IND) submission, clinical trial and commercialization. \u00a0DotBio will receive upfront and research
\npayments, and is eligible for milestones and royalties, with the option to
\nobtain additional stakes in these projects by participating in their later-stage
\ndevelopment.<\/p>\n
\n
<\/p>\n
\nmajor eye diseases in China were much larger than those in the United States,
\nwhereas the size of China’s ophthalmic drug market accounted for only one-fifth
\nof that of the United States in 2019, indicating a strong growth potential of
\nChina’s ophthalmic drug market. Among the four types of retinal diseases,
\nprevalence of wet AMD increased more rapidly than the other three because of
\naging population. The majority of patients with wet AMD experience severe vision loss in the affected eye within
\napproximately two years after diagnosis of the disease. The prevalence of wet AMD in China was
\n3.4 million in 2017 and is expected to reach 4.0 million in 2022 and 4.8
\nmillion in 2030. We believe that there is a significant commercial demand for
\nthe treatment of Wet AMD. As people are gaining awareness on the importance of
\neye examination, they can be given access to the life-changing, sight-saving
\ntherapies. The unmet needs in the AMD market are set to be addressed in the
\ncoming years.<\/p>\n
\n
<\/p>\n
\npotential of our DotBody technology in the ophthalmology space. Our stabilized and
\nhumanized VH domains, also known as “DotBodies”, are a superior alternative to
\nthe camelid-derived VHH domains\u00a0 (“nanobodies”),
\nby being generated synthetically without the use of animals, and being derived
\nfrom human VH domain sequences present in normal monoclonal antibodies. These DotBodies
\nhave properties that make them superior in many ways compared to conventional
\nantibodies. They are the smallest known human antibody fragments that are still
\ncapable of antigen binding with high affinity and specificity. They are also highly
\nmodular, allowing the rapid development of multi-valent and multi-specific
\ntherapies. We expect their use in a growing number of applications including
\nophthalmology because of these unique properties.” said Dr. Ignacio Asial, CEO
\nand Founder of DotBio. <\/p>\n
\n
<\/p>\n
\ninnovation across multiple verticals. We want to \u00a0combine different protein engineering and
\nformulation technologies together to create unique products with a competitive edge
\nin the clinic. In addition, Uni-Bio has a wealth of experience in fermentation
\n\/purification\/QA\/QC of E.coli-expressed proteins. Therefore, we are capable to
\n“scale up” and commercialize products effectively. In the past, the Group has
\nalso successfully launched ophthalmology biologic product such as GeneSoft\u2122 eye
\ndrop. We hope to replicate the same success in the next generation products
\nco-developed with DotBio.” said Mr. Kingsley Leung, Chairman of Uni-Bio Science
\nGroup.<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"